Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients

(2018) S T Kim et al.   ANNALS OF ONCOLOGY

Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer

(2018) Giulia Siravegna et al.   CANCER CELL

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

(2018) Oliver A. Zill et al.   CLINICAL CANCER RESEARCH

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies

(2018) Justin I. Odegaard et al.   CLINICAL CANCER RESEARCH

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

(2018) Seung Tae Kim et al.   NATURE MEDICINE

Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma

(2018) Steven B. Maron et al.   Cancer Discovery

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

(2018) Clara Montagut et al.   JAMA Oncology

KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.

(2018) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.

(2018) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.

(2018) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

(2017) Teresa Davoli et al.   SCIENCE

DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer

(2017) Soulafa Mamlouk et al.   Nature Communications

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

(2017) Eirini Pectasides et al.   Cancer Discovery

Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study

(2016) Nirmala Pathmanathan et al.   Asia-Pacific Journal of Clinical Oncology

Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)

(2016) Sook Ryun Park et al.   EUROPEAN JOURNAL OF CANCER

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

(2016) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

(2016) Andrea Sartore-Bianchi et al.   LANCET ONCOLOGY

HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease

(2016) Michelina Amato et al.   PATHOLOGY & ONCOLOGY RESEARCH

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation

(2016) D. S. Hong et al.   Cancer Discovery

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites

(2015) O. Gumusay et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

(2015) Richard B. Lanman et al.   PLoS One

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET